Shorts

Kirollos Hanna, PharmD, BCPS, BCOP, broke down the correlation between ctDNA positivity and event-free survival in muscle-invasive bladder cancer.

1:30

Who Should Receive Adjuvant Immunotherapy After a Radical Cystectomy?

4 days ago

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC

1:19

The Reality of Biopsy Needle Conservation Requests

5 days ago

Harriet Borofsky, MD

1:15

How the Brevera Recall Triggered a Supply Chain Cascade

6 days ago

Harriet Borofsky, MD

Sivraj Muralikrishnan, MD, highlighted findings from the RASolute 302 study evaluating daraxonrasib as a potential new benchmark for patients with RAS-mutated pancreatic cancer.

1:10

Practice-Changing Data in Metastatic PDAC: A New Second-Line Standard?

13 days ago

Sivraj Muralikrishnan, MD

0:55

What Does LIBRETTO-432 Mean for Precision Oncology in RET+ NSCLC?

14 days ago

Sivraj Muralikrishnan, MD

In this video, Benoit Tessoulin, MD, PhD, hematologist at Centre Hospitalier Universitaire de Nantes, Nantes, France, discussed the potential of combining epcoritamab plus lenalidomide and rituximab for patients with follicular lymphoma experiencing a relapse after first-line chemoimmunotherapy.

0:41

How the EPCORE FL-1 Regimen is Changing the Follicular Lymphoma Landscape

20 days ago

Benoit Tessoulin, MD, PhD

In a conversation with CancerNetwork® at the opening of the Melchiorre Cancer Center at Cooperman Barnabas Medical Center, a new cancer facility from RWJBarnabas Health and Rutgers Cancer Institute, Steven K. Libutti, MD, FACS, highlighted how the center will facilitate seamless multidisciplinary collaboration to enhance patient care.

1:00

Designing a New Cancer Center to Facilitate Seamless Teamwork

22 days ago

Steven K. Libutti, MD

Guilherme Perini, MD, PhD, explained how dual checkpoint inhibition serves as a proof of concept for reversing immunotherapy resistance while preserving quality of life in heavily pretreated classic Hodgkin lymphoma.

1:08

Prioritizing Response Durability in Heavily Pretreated Hodgkin Lymphoma

24 days ago

Guilherme Fleury Perini, MD, PhD

Chinmay Jani, MD, joined CancerNetwork® in the studio to discuss ongoing work dedicated to overcoming immunotherapy resistance and harnessing novel biomarkers to elevate the quality of care for patients with lung cancer.

0:34

Can Lung Cancer Become a Chronic Disease?

25 days ago

Chinmay Jani, MD

0:35

Building a “Layer of Ethics” Into Oncologic AI Tools

a month ago

Chinmay Jani, MD

Matthew Matasar, MD, noted that while the frontMIND regimen has caught everyone’s attention, the lack of a statistically significant overall survival benefit means treating oncologists must carefully balance efficacy against incremental adverse effects and scheduling burdens.

0:49

Weighing the frontMIND PFS Benefit Vs Toxicity in High-Risk DLBCL

a month ago

Matthew J. Matasar, MD

Eric Miller, MD, discussed clinical thresholds that may prompt the adoption of a bladder-sparing approach among patients with urothelial carcinoma.

1:01

Patient Values Inform Treatment Decision-Making in Urothelial Carcinoma

a month ago

Eric Miller, MD

0:51

Exploring the Weight Loss Potential of GLP-1 Agonists in Patients With Breast Cancer

a month ago

Sherry Shen, MD

1:22

How GLP-1 Agonists Improve Overall Survival in Breast Cancer Care

a month ago

Sherry Shen, MD

Yan Leyfman, MD, broke down a review article titled “Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma”, which was published in the journal ONCOLOGY in May 2026.

0:58

Investigating the Evolution of Cellular Therapy in Multiple Myeloma

a month ago

Yan Leyfman, MD

Bachy noted that the initiation of the phase 3 MorningLyte trial (NCT06284122) was directly inspired by the phase 1b results, expressing that the same mosunetuzumab regimen was being compared against conventional chemoimmunotherapy.

0:57

Phase 1 Mosunetuzumab Data Inspires Phase 3 MorningLyte Study

a month ago

1:03

How is CAR T-Cell Therapy Transforming Expectations in Multiple Myeloma?

a month ago

Yan Leyfman, MD

1:11

How a Nurse Builds Deep Trust with Patients

a month ago

Kassiane Saieed, DNP, AGNP-C

In a conversation with CancerNetwork® at the European Hematology Association (EHA) 2026 Congress, Matthew S. Davids, MD, MMSc, discussed what updated findings from the phase 3 BRUIN CLL-322 trial (NCT04965493) represent for the clinical utility of pirtobrutinib (Jaypirca) plus venetoclax (Venclexta) and rituximab (Rituxan; PVR) for patients with previously treated chronic lymphocytic leukemia.

0:48

When is Pirtobrutinib Triplet Therapy Most Useful in CLL Care?

a month ago

Matthew S. Davids, MD, MMSc

1:22

Why Fertility Talks Can’t Wait After a Cancer Diagnosis

a month ago

Kassiane Saieed, DNP, AGNP-C

Jorge E. Cortes, MD, spoke with CancerNetwork® about updated findings from the phase 3 ASC4FIRST trial (NCT04971226) showing improved responses and tolerability with asciminib (Scemblix) vs other tyrosine kinase inhibitors like imatinib (Gleevec) among those with chronic myeloid leukemia in chronic phase (CML-CP).

0:58

Perseverance is Key With Asciminib in Chronic Myeloid Leukemia

a month ago

Jorge E. Cortes, MD

Karen Reckamp, MD, MS, challenged leadership to move beyond traditional, volume-based work relative value unit (wRVU) metrics.

0:52

Reexamining Investigator Incentives for Clinical Research Beyond RVUs

a month ago

Karen L. Reckamp, MD

0:51

Will Multi-Targeted Regimens Spell a Reduction of Chemotherapy in DLBCL?

a month ago

Sonali M. Smith, MD

0:50

Can Tafasitamab/Lenalidomide Prolong Remission in High-Risk DLBCL?

a month ago

Sonali M. Smith, MD

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Hannah Goulart, MD, spoke about findings from an analysis evaluating revumenib (Revuforj) maintenance after allogeneic stem cell transplantation among patients with acute myeloid leukemia.

0:35

Does Revumenib Have a Role in The Pediatric AML Setting?

a month ago

Hannah Goulart, MD

David M. Waterhouse, MD, MPH, discussed findings from a chart review analysis, contextualized by a need to improve prostate cancer testing rates in the US.

Developing Governance for AI in Prostate Cancer Genetic Testing

a month ago

David M. Waterhouse, MD, MPH

0:54

How Does Vorasidenib Impact the Tumor Microenvironment?

2 months ago

Timothy F. Cloughesy, MD

Fred Saad, MD, FRCS, CQ, FCAHS, stated that no significant differences in higher grade or serious adverse effects emerged among patients regardless of disease volume.

1:06

AE Profile of Lu-177-PSMA-617 Similar Among Low, High Volume mHPSC Groups

2 months ago

Fred Saad, MD

Praful Ravi, MB, BChir, MRCP, highlighted that residual PSMA-avid disease remained detectable on PET imaging in 100% of patients with metastatic HSPC at the 6-month mark.

0:59

PSMAtrack: 100% of mHSPC Group Show Residual PSMA-Avid Disease at 6 Months

2 months ago

Praful Ravi, MB, BChir, MRCP

How Does Abemaciclib Toxicity Translate from Breast to Gynecologic Cancers?

Shorts

Trending on CancerNetwork

ctDNA MRD Guidance in Bladder Cancer: Pharmacy Specialist on NCCN Updates

Sequencing Treatment after EV-Pembro in Urothelial Carcinoma

Pembrolizumab Monotherapy Improves PFS in Frontline dMMR Endometrial Cancer

All-Oral AML Regimen Eases Burden on Busy Infusion Centers

How Do Updated NCCN Guidelines and ctDNA Data Reshape MIBC Treatment?